Skip to main content

Table 3 Absolute benefit increase and number needed to treat by comparator and study

From: Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

Single Goals

 

DURATION-4

DURATION-2

DURATION-3

Therapy

% Reaching Goal (N)

ABI

(95% CI)

NNT

(95% CI)

% Reaching Goal (N)

ABI

(95% CI)

NNT

(95% CI)

% Reaching Goal (N)

ABI

(95% CI)

NNT

(95% CI)

HbA1c <7.0%

ExQW

61.6%

  

58.6%

  

59.0%

  
 

(237)

  

(157)

  

(222)

  

Met

54.8%

6.8%

15

      
 

(239)

(-2%, 15%)

(7, ∞, -49)

      

Sita

41.4%

20.2%

5

27.7%

30.9%

4

   
 

(152)

(10%, 30%)

(4, 10)

(155)

(20%, 41%)

(3, 5)

   

Pio

58.5%

3.0%

34

43.4%

15.2%

7

   
 

(157)

(-7%, 13%)

(8, ∞, -15)

(159)

(4%, 26%)

(4, 24)

   

IG

      

46.5%

12.5%

8

       

(215)

(3%, 22%)

(5, 32)

HbA1c ≤6.5%

ExQW

48.2%

  

38.8%

  

42.2%

  
 

(247)

  

(160)

  

(232)

  

Met

36.2%

12.0%

9

      
 

(243)

(3%, 20%)

(5, 31)

      

Sita

24.5%

23.7%

5

14.6%

24.2%

5

   
 

(163)

(14%, 32%)

(4, 7)

(164)

(15%, 33%)

(3, 7)

   

Pio

40.9%

7.3%

14

26.1%

12.7

8

   
 

(159)

(-3%, 17%)

(6, ∞, -38)

(165)

(3%, 23%)

(5, 40)

   

IG

      

28.1%

14.1%

8

       

(221)

(5%, 23%)

(5, 19)

No Weight Gain

ExQW

72.6%

  

78.1%

  

84.1%

  
 

(248)

  

(160)

  

(233)

  

Met

76.8%

-4.2%

-24

      
 

(246)

(-12%, 3%)

(29, ∞, -9)

      

Sita

65.0%

7.6%

14

59.6%

18.5%

6

   
 

(163)

(-1%, 17%)

(6, ∞, -69)

(166)

(8%, 28%)

(4, 12)

   

Pio

36.8%

35.8%

3

24.2%

53.9%

2

   
 

(163)

(26%, 45%)

(3, 4)

(165)

(44%, 62%)

(2, 3)

   

IG

      

33.2%

50.9%

2

       

(223)

(43%, 58%)

(2, 3)

Any Weight Loss

ExQW

68.5%

  

76.9%

  

79.0%

  
 

(248)

  

(160)

  

(233)

  

Met

72.8%

-4.3%

-24

      
 

(246)

(-12%, 4%)

(27, ∞, -9)

      

Sita

55.9%

12.7%

8

59.0%

17.9%

6

   
 

(163)

(3%, 22%)

(5, 32)

(166)

(8%, 27%)

(4, 13)

   

Pio

33.1%

35.4%

3

21.2%

55.7%

2

   
 

(163)

(26%, 44%)

(3, 4)

(165)

(46%, 64%)

(2, 3)

   

IG

      

30.5%

48.5%

3

       

(223)

(40%, 56%)

(2, 3)

No Major/Minor Hypoglycemia

ExQW

98.0%

  

98.8%

  

88.4%

  
 

(248)

  

(160)

  

(233)

  

Met

100.0%

-2.0%

-50

      
 

(246)

(-5%, 0%)

(∞, -22)

      

Sita

100.0%

-2.0%

-50

97.0%

1.8%

56

   
 

(163)

(-5%, 1%)

(175, ∞, -22)

(166)

(-2%, 6%)

(17, ∞, -56)

   

Pio

100.0%

-2.0%

-50

98.8%

0

N/A

   
 

(163)

(-5%, 1%)

(175, ∞, -22)

(165)

(-3%, 3%)

    

IG

      

69.5%

18.9%

6

       

(223)

(12%, 26%)

(4, 9)

SBP<130 mm Hg

ExQW

39.7%

  

56.9%

  

25.3%

  
 

(126)

  

(58)

  

(154)

  

Met

25.0%

14.7%

7

      
 

(124)

(3%, 26%)

(4, 32)

      

Sita

31.2%

8.5%

12

34.8%

22.1%

5

   
 

(93)

(-4%, 21%)

(5, ∞, -23)

(66)

(5%, 38%)

(3, 22)

   

Pio

32.2%

7.5%

14

39.1%

17.8%

6

   
 

(87)

(-6%, 20%)

(5, ∞, -18)

(69)

(0%, 34%)

(3, 244)

   

IG

      

21.3%

4.0%

25

       

(136)

(-6%, 14%)

(8, ∞, -17)

FBG <6.99 mmol/L (<126 mg/dL)

ExQW

47.0%

  

54.9%

  

38.6%

  
 

(219)

  

(122)

  

(215)

  

Met

34.1%

12.9%

8

      
 

(217)

(4%, 22%)

(5, 27)

      

Sita

20.8%

26.2%

4

27.4%

27.5%

4

   
 

(144)

(16%, 35%)

(3, 7)

(135)

(16%, 38%)

(3, 7)

   

Pio

48.3%

-1.3%

-77

44.5%

10.4%

10

   
 

(145)

(-12%, 9%)

(11, ∞, -9)

(137)

(-2%, 22%)

(5, ∞, -57)

   

IG

      

51.5%

-12.9%

-8

       

(200)

(-22%, -3%)

(-5, -30)

LDL <2.59 mmol/L (100 mg/dL)

ExQW

20.2%

  

29.8%

  

32.3%

  
 

(168)

  

(84)

  

(130)

  

Met

23.1%

-2.9%

-35

      
 

(160)

(-12%, 6%)

(17, ∞, -9)

      

Sita

13.8%

6.4%

16

21.6%

8.2%

13

   
 

(109)

(-3%, 15%)

(7, ∞, -33)

(97)

(-4%, 21%)

(5, ∞, -22)

   

Pio

13.0%

7.2%

14

19.4%

10.4%

10

   
 

(115)

(-2%, 16%)

(7, ∞, -52)

(103)

(-2%, 23%)

(5, ∞, -53)

   

IG

      

15.3%

17.0%

6

       

(124)

(7%, 27%)

(4, 15)

Composite Goals

HbA1c <7.0%, No Weight Gain, No Hypoglycemia

ExQW

48.4%

  

48.1%

  

46.8%

  
 

(248)

  

(160)

  

(233)

  

Met

48.0%

0.4%

250

      
 

(246)

(-8%, 9%)

(11, ∞, -12)

      

Sita

34.4%

14.0%

8

22.3

25.8%

4

   
 

(163)

(4%, 23%)

(5, 24)

(166)

(16%, 35%)

(3, 7)

   

Pio

21.5%

26.9%

4

9.7%

38.4%

3

   
 

(163)

(18%, 35%)

(3, 6)

(165)

(29%, 47%)

(3, 4)

   

IG

      

13.0%

33.8%

3

       

(223)

(26%, 41%)

(3, 4)

HbA1c ≤6.5%, No Weight Gain, No Hypoglycemia

ExQW

39.1%

  

32.5%

  

30.5%

  
 

(248)

  

(160)

  

(233)

  

Met

32.9%

6.2%

17

      
 

(246)

(-2%, 15%)

(7, ∞, -44)

      

Sita

19.6%

19.5%

6

12.0%

20.5%

5

   
 

(163)

(11%, 28%)

(4, 10)

(166)

(12%, 29%)

(4, 9)

   

Pio

17.2%

21.9%

5

5.5%

27.0%

4

   
 

(163)

(13%, 30%)

(4, 8)

(165)

(19%, 35%)

(3, 6)

   

IG

      

9.4%

21.1%

5

       

(223)

(14%, 28%)

(4, 8)

HbA1c<7%, SBP <130 mm Hg, LDL <2.59 mmol/L

ExQW

15.0%

  

22.6%

  

17.7%

  
 

(246)

  

(159)

  

(231)

  

Met

13.4%

1.6%

63

      
 

(246)

(-5%, 8%)

(13, ∞, -22)

      

Sita

5.0%

10.0%

10

11.6%

11.0%

10

   
 

(160)

(4%, 16%)

(7, 25)

(164)

(3%, 19%)

(6, 36)

   

Pio

8.7%

6.3%

16

14.6%

8.0%

13

   
 

(161)

(0%, 12%)

(9, ∞, -285)

(164)

(-1%, 16%)

(7, ∞, -197)

   

IG

      

10.3%

7.4%

14

       

(223)

(1%, 14%)

(8, 101)

HbA1c ≤6.5%, SBP<130 mm Hg, LDL <2.59 mmol/L

ExQW

12.9%

  

16.9%

  

12.9%

  
 

(248)

  

(160)

  

(232)

  

Met

7.7%

5.2%

20

      
 

(246)

(0%, 11%)

(10, ∞, -490)

      

Sita

4.3%

8.6%

12

6.1%

10.8%

10

   
 

(163)

(3%, 14%)

(8, 34)

(165)

(4%, 18%)

(6, 26)

   

Pio

6.2%

6.7%

15

9.1%

7.8%

13

   
 

(161)

(1%, 12%)

(9, 152)

(165)

(0%, 15%)

(7, 220 )

   

IG

      

5.8%

7.1%

15

       

(223)

(2%, 13%)

(8, 58)

  1. ABI, Absolute Benefit Increase; NNT, number needed to treat;
  2. NNT compares ExQW with indicated comparator; an infinity limit (∞) is shown for the 95% CI of the NNT if the 95% CI of the ABI contains zero;
  3. N refers to subjects not at goal at baseline.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840